| Bioactivity | Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2]. |
| Name | Vazegepant |
| CAS | 1337918-83-8 |
| Formula | C36H46N8O3 |
| Molar Mass | 638.80 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929. [2]. Gene M Dubowchik,Charles M Conway,Alison W Xin.Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. |